Biological Sciences and Bioengineering Program, Faculty of Engineering and Natural Sciences, Sabanci University, Orhanli-Tuzla, 34956 Istanbul, Turkey.
Curr Med Chem. 2013;20(27):3358-69. doi: 10.2174/09298673113209990003.
Studies with breast cancer cells, showed that microRNAs (miRNAs) act as regulators of signaling pathways playing a key role in tumor progression and being targeted in chemotherapy. Deregulation of these pathways by altered miRNA expression or single nucleotide polymorphisms (SNPs) found in certain miRNA genes have been shown to lead tumor growth, metastasis, angiogenesis, and drug resistance. miRNAs have also been indicated to act on stem cell selfrenewal and alter signal transduction in cancer stem-like cells (CSC), which are resistant to many conventional therapies and account for the inability of these therapies to cure cancers. By considering these findings, miRNAs are proposed as potential novel biomarkers as well as therapeutic targets in new anti-cancer strategies. In this review, the miRNAs found to be involved in breast cancer chemoresistance will be covered together with breast CSC and their contribution to chemotherapy resistance.
研究表明，微小 RNA（miRNAs）作为信号通路的调节剂发挥作用，在肿瘤进展中起着关键作用，并成为化疗的靶点。miRNA 表达的改变或某些 miRNA 基因中发现的单核苷酸多态性（SNP）会导致这些通路失调，从而导致肿瘤生长、转移、血管生成和耐药性。研究表明，miRNAs 还可以作用于干细胞自我更新，并改变癌症干细胞样细胞（CSC）中的信号转导，CSC 对许多常规疗法具有耐药性，这也是这些疗法无法治愈癌症的原因。考虑到这些发现，miRNAs 被提议作为新的抗癌策略中潜在的新型生物标志物和治疗靶点。在这篇综述中，将讨论与乳腺癌化疗耐药性相关的 miRNA，以及乳腺癌 CSC 及其对化疗耐药性的贡献。
